Inception 1 Inc.

Necessity mothered the build-to-buy strategy. Some thought good times might kill it. At a time when venture capital found few exit opportunities for early-stage companies, build-to-buy helped mitigate

Versant Ventures’ Inception Sciences Inc. has been one of biotech’s most active asset-financing experiments. Now, to fuel international expansion, the firm wants to clone it in Canada, where the o

Financings Biopharma financing in the final quarter of 2012 reached $4.2 billion, a 36% increase over Q3’s $3.1 billion, again boosted by a strong showing from follow-on public offerings. The fourth q

Venture firms that have begun experimenting with asset-based financing hope to reap returns from relatively quick, clean exits, some in the next year or two. But as many await the first outcomes of th